-
Heart Failure Outcomes With Volume-Guided ManagementJE Strobeck, J Feldschuh, WL Miller. -
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionSD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray,
-
Association Between Functional Impairment and Medication Burden in Adults with Heart FailureGoyal P, Bryan J, Kneifati-Hayek J et al.
-
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Pieske B Tschöpe C, de Boer RA et al.
-
Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart FailureESJ Tan, S-P Chan, O-W Liew et al.
-
Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future DirectionsHsu JJ, Ziaeian B, Fonarow GC.
-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators.
-
Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionMcMurray JJV, SD Solomon, DAPA-HF Committees and Investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
